BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 19, 2020
Product Development

Slotting anti-inflammatories into COVID-19 treatment

While repurposed agents for COVID-19 have largely focused on suppressing SARS-CoV-2, there is a strong case to be made for evaluating anti-inflammatory agents in patients with severe disease. As more emerges about the disease, it’s...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

Eleven COVID-19 patients discharged after receiving Ascletis drug  Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19 patients in a cohort receiving Ganovo danoprevir plus ritonavir in a Chinese Phase IV trial have been discharged from...
BioCentury | Feb 27, 2020
Product Development

COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic. Separately, Gilead started a pair of Phase III trials of remdesivir to treat COVID-19, bringing the total number of trials testing the...
BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BC Extra | Jun 17, 2019
Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
BC Extra | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 30, 2018
Company News

Ascletis adds HBV therapy to portfolio through Roche partnership

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Nov. 20 with exclusive rights to marketed HBV drug Pegasys...
BC Extra | Nov 20, 2018
Company News

Ascletis adds marketed HBV drug from Roche to Chinese portfolio

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Tuesday with exclusive rights to marketed HBV drug Pegasys peginterferon...
Items per page:
1 - 10 of 145